Literature DB >> 9920498

Neuronal death in glaucoma.

H A Quigley1.   

Abstract

Glaucoma is recognized to have its major detrimental effect upon the eye by killing retinal ganglion cells. The process of cell death appears to be initiated at the optic nerve head, though other sites of injury are possible but unsubstantiated. At present the injury at the nerve head seems related to the level of the eye pressure, but its detailed mechanism is as yet unexplained. There is a greater loss of ganglion cells from some areas of the eye, and this feature of glaucoma seems related to the regional structure of the supporting connective tissues of the optic nerve head. Larger retinal ganglion cells have been consistently shown to have somewhat greater susceptibility to injury in glaucoma, though all cells are injured, even early in the process. Ganglion cells die by apoptosis in human and experimental glaucoma, opening several potential areas for future therapies to protect them from dying. Neurotrophin deprivation is one possible cause of cell death and replacement therapy is a potential approach to treatment.

Entities:  

Mesh:

Year:  1999        PMID: 9920498     DOI: 10.1016/s1350-9462(98)00014-7

Source DB:  PubMed          Journal:  Prog Retin Eye Res        ISSN: 1350-9462            Impact factor:   21.198


  252 in total

Review 1.  Ganglion cell death in glaucoma: what do we really know?

Authors:  N N Osborne; J P Wood; G Chidlow; J H Bae; J Melena; M S Nash
Journal:  Br J Ophthalmol       Date:  1999-08       Impact factor: 4.638

Review 2.  A hypothesis to explain ganglion cell death caused by vascular insults at the optic nerve head: possible implication for the treatment of glaucoma.

Authors:  N N Osborne; J Melena; G Chidlow; J P Wood
Journal:  Br J Ophthalmol       Date:  2001-10       Impact factor: 4.638

3.  Influence of post-LASIK corneal healing on scanning laser polarimetric measurement of the retinal nerve fibre layer thickness.

Authors:  G Holló; Z Z Nagy; P Vargha; I Süveges
Journal:  Br J Ophthalmol       Date:  2002-06       Impact factor: 4.638

4.  Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action.

Authors:  Grace C Shih; David J Calkins
Journal:  Expert Rev Ophthalmol       Date:  2012-04

Review 5.  A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma.

Authors:  Claude F Burgoyne
Journal:  Exp Eye Res       Date:  2010-09-16       Impact factor: 3.467

Review 6.  Steroid-induced ocular hypertension/glaucoma: Focus on pharmacogenomics and implications for precision medicine.

Authors:  M Elizabeth Fini; Stephen G Schwartz; Xiaoyi Gao; Shinwu Jeong; Nitin Patel; Tatsuo Itakura; Marianne O Price; Francis W Price; Rohit Varma; W Daniel Stamer
Journal:  Prog Retin Eye Res       Date:  2016-09-22       Impact factor: 21.198

7.  Sustained ocular hypertension induces dendritic degeneration of mouse retinal ganglion cells that depends on cell type and location.

Authors:  Liang Feng; Yan Zhao; Miho Yoshida; Hui Chen; Jessica F Yang; Ted S Kim; Jianhua Cang; John B Troy; Xiaorong Liu
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-02-07       Impact factor: 4.799

8.  Biaxial mechanical testing of posterior sclera using high-resolution ultrasound speckle tracking for strain measurements.

Authors:  Benjamin Cruz Perez; Junhua Tang; Hugh J Morris; Joel R Palko; Xueliang Pan; Richard T Hart; Jun Liu
Journal:  J Biomech       Date:  2013-12-24       Impact factor: 2.712

9.  High-dose radiation with bone marrow transfer prevents neurodegeneration in an inherited glaucoma.

Authors:  Michael G Anderson; Richard T Libby; Douglas B Gould; Richard S Smith; Simon W M John
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-09       Impact factor: 11.205

10.  TRPV1: contribution to retinal ganglion cell apoptosis and increased intracellular Ca2+ with exposure to hydrostatic pressure.

Authors:  Rebecca M Sappington; Tatiana Sidorova; Daniel J Long; David J Calkins
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-10-24       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.